Show notes
BrainStorm wants to hear from you! Send us a text. The quest to speed up clinical trials is personal for John Dwyer, CEO of the Global Alzheimer's Platform (GAP). A long-time UsA2 advocate, he’s been motivated by the generations of family members lost to Alzheimer's and Parkinson's disease. Dwyer shares with BrainStorm host Meryl Comer the critical challenges of NIH funding cuts by the Trump Administration, forcing many trial sites to shut down at a time of new FDA-cleared blood tests for ear...

